House, Senate Panels Agree On Compounder Oversight Bill

Law360, New York (September 26, 2013, 5:18 PM EDT) -- Legislation that would give the U.S. Food and Drug Administration greater authority to regulate companies that compound sterile drugs has won bipartisan support as U.S. House and Senate committees overseeing health policy agreed on the bill, according to a Wednesday news release.

The Drug Quality and Security Act would require large-scale drug compounders to register with the FDA and become subject to agency oversight in the same way as traditional chemical drug manufacturers, according to dual releases by the Senate Health, Education, Labor and Pension Committee...
To view the full article, register now.